## **Medicines Safety Tablet Press**

Medicines safety newsletter for GPs, nurses and pharmacy teams NHS Northamptonshire ICB

Issue: 3 June 2025

### Spironolactone oral suspension compatibility with feeding tubes.

New licensed spironolactone oral suspensions are available (<u>Urospir from Rosemont Pharmaceuticals</u> and <u>Qaialdo from Nova Labs</u>). Previously only unlicensed specials were available.

There is a difference in the formulation of these licensed products. Urospir® brand is contraindicated for use with devices such as enteral tubes which contain polystyrene or PVC. Qaialdo® brand can be used with feeding tubes. Please check that prescriptions are for the appropriate product depending on whether the patient takes medication orally or via feeding tube. We recommend prescribing as Qaialdo® brand for patients using a feeding tube to ensure an appropriate product is dispensed.

Qaialdo® is available as 10mg/ml oral suspension. This is the strength recommended for use in children following the <a href="NPPG">NPPG Position Statement: Using Standardised Concentrations of Liquid Medicines in Children</a>

# ➤ Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelines

The MHRA has issued a Drug Safety Update reminding healthcare professionals and patients about the risk of severe asthma attacks and increased mortality associated with overuse of SABA inhalers with or without anti-inflammatory maintenance therapy in patients with asthma. The <a href="https://docs.ps.com/BTS/NICE/SIGN">BTS/NICE/SIGN</a> guidance now recommends that the majority of people with asthma should be controlled on either Anti-Inflammatory Reliever (AIR) or Maintenance And Reliever Therapy (MART) treatment without the need for SABA. <a href="https://markaidu.com/MHRA">MHRA</a> advice

### Eclipse – valproate / valproic acid search

The Eclipse platform has a search that identifies females under 55yrs old currently prescribed valproate/valproic acid. This may help practices to identify patients for monitoring, review and ARAF (Annual Risk Acknowledgement Form) status. To access follow the steps below from the landing page:



### > Opioid Patient Information Leaflet

A new Northamptonshire Opioid Patient Information Leaflet is available on the <u>Primary Care Portal</u>. This is also available on the <u>GPA federation</u> website with a range of other resources and advice to support patients in managing and living well with pain.